Presence of Candida cell wall derived polysaccharides in the sera of intensive care unit patients: Relation with candidaemia and Candida colonisation

Critical Care

Volumn 18, Issue 3, 2014, Pages

  Poissy, Julien ^a,b,c   Sendid, Boualem ^a,b,c   Damiens, Sébastien ^a,b   Ichi Ishibashi, Ken ^d   François, Nadine ^c   Kauv, Marie ^a,c   Favory, Raphaël ^a,c   Mathieu, Daniel ^a,c   Poulain, Daniel ^a,b,c  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Tokyo University of Pharmacy and Life Science   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; BETA 1,3 GLUCAN; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; HYPERTENSIVE FACTOR; MANNAN; VORICONAZOLE; ANTIBODY; BETA GLUCAN; BETA-1,3-GLUCAN; BIOLOGICAL MARKER; FUNGAL POLYSACCHARIDE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNGAL CELL; FUNGAL COLONIZATION; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; MALE; RETROSPECTIVE STUDY; AGED; BLOOD; CELL WALL; EARLY DIAGNOSIS; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY;

AGED; ANTIBODIES; BETA-GLUCANS; BIOLOGICAL MARKERS; CANDIDEMIA; CASE-CONTROL STUDIES; CELL WALL; EARLY DIAGNOSIS; FEMALE; FUNGAL POLYSACCHARIDES; HUMANS; INTENSIVE CARE UNITS; MALE; MANNANS; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84903224185     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13953     Document Type: Article

References (43)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139, 12700374.
2. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177. 10.1086/378745, 14557960.
3. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011, 39:665-670. 10.1097/CCM.0b013e318206c1ca, 21169817.
4. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645. 10.1128/AAC.49.9.3640-3645.2005, 1195428, 16127033.
5. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012, 54:1739-1746. 10.1093/cid/cis305, 22423135.
6. Clancy CJ, Nguyen MH. Finding the 'missing 50%' of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013, 56:1284-1292. 10.1093/cid/cit006, 23315320.
7. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996, 33:23-32. 10.1016/S0163-4453(96)92700-0, 8842991.
8. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diag Microbiol Infect Dis 1993, 17:103-109.
9. Meyer MH, Letscher-Bru V, Jaulhac B, Waller J, Candolfi E. Comparison of Mycosis IC/F and plus Aerobic/F media for diagnosis of fungemia by the bactec 9240 system. J Clin Microbiol 2004, 42:773-777. 10.1128/JCM.42.2.773-777.2004, 344513, 14766852.
10. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, . Infectious Diseases Society of America Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635, Infectious Diseases Society of America.
11. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, Jensen HE, Lass-Florl C, Richardson MD, Akova M, Bassetti M, Calandra T, Castagnola E, Cornely OA, Garbino J, Groll AH, Herbrecht R, Hope WW, Kullberg BJ, Lortholary O, Meersseman W, Petrikkos G, Roilides E, Viscoli C, Ullmann AJ. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012, 18:9-18.
12. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, . Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup.
13. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Prospective survey of (1 → 3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011, 49:58-61. 10.1128/JCM.01240-10, 3020467, 21048005.
14. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821. 10.1086/588660, 2671227, 18462102.
15. Obayashi T, Yoshida M, Mori T, Goto H, Yasuoka A, Iwasaki H, Teshima H, Kohno S, Horiuchi A, Ito A, Yamaguchi H, Shimada K, Kawai T. Plasma (1 → 3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995, 345:17-20. 10.1016/S0140-6736(95)91152-9, 7799700.
16. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011, 52:750-770. 10.1093/cid/ciq206, 21367728.
17. Ueda Y, Ohwada S, Abe Y, Shibata T, Iijima M, Yoshimitsu Y, Koshiba T, Nakata M, Ueda T, Kawabata S. Factor G utilizes a carbohydrate-binding cleft that is conserved between horseshoe crab and bacteria for the recognition of beta-1,3-D-glucans. J Immunol 2009, 183:3810-3818.
18. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1 → 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659. 10.1086/432470, 16080087.
19. Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, Shields RM, Cheng S, Mitsani D, Vadnerkar A, Silveira FP, Kleiboeker SB, Clancy CJ. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012, 54:1240-1248. 10.1093/cid/cis200, 22431804.
20. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1 → 3)-beta-D-glucan assay, Candida score, and colonization index. Crit Care 2011, 15:R249. 10.1186/cc10507, 3334800, 22018278.
21. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1 → 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbol 2008, 46:1009-1013.
22. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diag Lab Immunol 2003, 10:882-885.
23. Theel ES, Doern CD. Point-Counterpoint: β-D-glucan is an important test in the diagnosis of invasive fungal infections. J Clin Microbiol 2013, 51:3478-3483. 10.1128/JCM.01737-13, 3889722, 23850953.
24. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, Marchetti O. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008, 46:878-885. 10.1086/527382, 18260755.
25. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-Beta-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 2012, 55:521-526. 10.1093/cid/cis456, 22573851.
26. Ishibashi K, Yoshida M, Nakabayashi I, Shinohara H, Miura NN, Adachi Y, Ohno N. Role of anti-beta-glucan antibody in host defense against fungi. FEMS Immunol Med Microbiol 2005, 44:99-109. 10.1016/j.femsim.2004.12.012, 15780582.
27. Chiani P, Bromuro C, Cassone A, Torosantucci A. Anti-beta-glucan antibodies in healthy human subjects. Vaccine 2009, 27:513-519. 10.1016/j.vaccine.2008.11.030, 19041357.
28. Sendid B, Dotan N, Nseir S, Savaux C, Vandewalle P, Standaert A, Zerimech F, Guery BP, Dukler A, Colombel JF, Poulain D. Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan. Clin Vaccine Immunol 2008, 15:1868-1877. 10.1128/CVI.00200-08, 2593178, 18971303.
29. Yauch L, Lam J, Levitz S. Direct inhibition of T-cell responses by the Cryptococcus capsula polysaccharide glucuronoxylomannan. PLoS Pathog 2006, 2:e120. 10.1371/journal.ppat.0020120, 1635532, 17096589.
30. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011, 11:275-288. 10.1038/nri2939, 21394104.
31. Held J, Kohlberger I, Rappold E, Busse Grawitz A, Hacker G. Comparison of (1 → 3)-beta-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol 2013, 51:1158-1164. 10.1128/JCM.02473-12, 3666776, 23363830.
32. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011, 55:532-538. 10.1128/AAC.01128-10, 3028765, 21078946.
33. Sendid B, Tabouret M, Poirot JL, Mathieu D, Fruit J, Poulain D. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999, 37:1510-1517. 84817, 10203514.
34. Damiens S, Poissy J, Francois N, Salleron J, Jawhara S, Jouault T, Poulain D, Sendid B. Mannose-binding lectin levels and variation during invasive candidiasis. J Clin Immunol 2012, 32:1317-1323. 10.1007/s10875-012-9748-2, 22833166.
35. Sendid B, Poirot JL, Tabouret M, Bonnin A, Caillot D, Camus D, Poulain D. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002, 51:433-442.
36. Morace G, Borghi E. Fungal infections in ICU patients: epidemiology and the role of diagnostics. Minerva Anestesiol 2010, 76:950-956.
37. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 2011, 1:37. 10.1186/2110-5820-1-37, 3224461, 21906271.
38. Charles PE, Dalle F, Aube H, Doise JM, Quenot JP, Aho LS, Chavanet P, Blettery B. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med 2005, 31:393-400. 10.1007/s00134-005-2571-y, 15711782.
39. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, Marchetti O. β-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference On Infection in Leukemia (ECIL3). Clin Infect Dis 2012, 54:633-643. 10.1093/cid/cir897, 22198786.
40. Schuster MG, Edwards JE, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Panzer H, Biswas P, Rex JH. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008, 149:83-90. 10.7326/0003-4819-149-2-200807150-00004, 18626047.
41. Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 2005, 143:857-869. 10.7326/0003-4819-143-12-200512200-00004, 16365467.
42. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis Clin Microbiol 2007, 26:271-276.
43. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, Balasini C, Utande-Vazquez A, De Gonzalez De Molina FJ, Blasco-Navalproto MA, López MJ, Charles PE, Martín E, Hernández-Viera MA, . Cava Study Group Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009, 37:1624-1633. 10.1097/CCM.0b013e31819daa14, 19325481, Cava Study Group.